Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd. C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Company’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.


CSE:RVV - Post by User

Comment by TheIceMan3on Sep 03, 2020 4:39pm
72 Views
Post# 31505657

RE: RVV / RVVTF THURSDAY 20min AFTER THE BELL RECAP

RE: RVV / RVVTF THURSDAY 20min AFTER THE BELL RECAP
Very interesting post GURU


TECHNICALGURU wrote: -IT'S THE.....  SAME OL' SITUATION HERE AT RVV / RVVTF

-FACTS STILL REMAIN.... NO REAL CHANGE HERE...


- The Company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time.


- It still Looks safe to go short here or stay in cash and either cover your short in the .14 to .17 range or look to get back in for a bullish bet in the .16 to .18 range.. 

 
 

Two common objectives of painting the tape are to lure unsuspecting investors into a security and to achieve a high closing price for the security.



SHORTS CALMLY STANDING THERE GROUND 

REVIVE THERAPEUTICS LTD. ORDINARY SHARES
$
RVVTF
 
view
Short Interest Ratio (Days To Cover)
0.1
Short Percent of Float
%
Short % Increase / Decrease
1,090 %
Short Interest (Shares Short)
2,031,000
Short Interest (Shares Short) - Prior
170,700

MARCH 18, 2020
- 33,535,000 AT .05 
THE SELLING WILL CONTINUE HERE FOR A WHILE

- 33,535,000 WARRENTS @ .07
- PLUS 3,018,150 WARRENTS @ .05 TO THE "BROKER WARRENTS"

APRIL 15, 2020
- 16,400,000 AT .05 THE SELLING WILL CONTINUE HERE FOR A WHILE

- 16,400,000 WARRENTS @ .07

- PLUS 1,476,000 WARRENTS @ .05 TO THE "BROKER WARRENTS"


Date: August 12th, 2020

1. New Options Granted:

Date of Grant: August 5th, 2020 and August 12th, 2020

Name of Optionee Position (Director/ Officer/ Employee/ Consultant/ Management Company Insider Yes or No? No. of Optioned Shares Exercise Price Expiry Date No. of Options Granted in Past 12 Months

Michael Frank Director & Officer Yes 6,000,000 $0.33 5-Aug-25 4,500,000

Fabio Chianelli Consultant No 2,500,000 $0.35 12-Aug-25 0

Derrick Welsh Consultant No 1,000,000 $0.35 12-Aug-25 0

Jayden Smit Consultant No 500,000 $0.35 12-Aug-25 0


Total Number of optioned shares proposed for acceptance: 10,000,000.

Other Presently Outstanding Options:
 
Name of Optionee
 
No. of Optioned
Shares(1)
 
Exercise
Price
 
Original Date
of Grant Expiry Date
 
William Jackson, director 100,000 $0.66 31-Jan-14 31-Jan-24
William Jackson, director 150,000 $0.60 11-Feb-15 11-Feb-25
William Jackson, director 150,000 $0.28 10-Apr-17 10-Apr-27
William Jackson, director 500,000 $0.07 27-Dec-19 27-Dec-24
 
Carlo Sansalone, ex-director 40,375 $0.30 9-Jul-13 9-Jul-23
Carlo Sansalone, ex-director 75,000 $0.66 31-Jan-14 31-Jan-24
Carlo Sansalone, ex-director 100,000 $0.60 11-Feb-15 11-Feb-25
Carlo Sansalone, ex-director 100,000 $0.28 10-Apr-17 10-Apr-27
Carlo Sansalone, consultant 350,000 $0.33 25-May-20 25-May-30
 
Carmelo Marrelli, officer 10,000 $0.66 31-Jan-14 31-Jan-24
Carmelo Marrelli, officer 20,000 $0.60 11-Feb-15 11-Feb-25
Carmelo Marrelli, officer 40,000 $0.28 10-Apr-17 10-Apr-27
Carmelo Marrelli, officer 500,000 $0.33 25-May-20 25-May-30
 
Dr. Bev Incledon, officer 10,000 $0.66 31-Jan-14 31-Jan-24
Dr. Bev Incledon, officer 10,000 $0.60 11-Feb-15 11-Feb-25
Dr. Bev Incledon, officer 25,000 $0.28 10-Apr-17 10-Apr-27
Dr. Bev Incledon, consultant 100,000 $0.33 25-May-20 25-May-30
 
Angela Fuda, ex-employee 20,000 $0.66 31-Jan-14 31-Jan-24
Angela Fuda, ex-employee 20,000 $0.60 11-Feb-15 11-Feb-25
Angela Fuda, ex-employee 100,000 $0.28 10-Apr-17 10-Apr-27
Angela Fuda, consultant 75,000 $0.33 25-May-20 25-May-30
 
Khazak Group Consulting Corp. 200,000 $0.60 11-Feb-15 11-Feb-25
Khazak Group Consulting Corp. 150,000 $0.28 10-Apr-17 10-Apr-27
 
BRI Clinical Research and
Development Inc.150,000 $0.28 10-Apr-17 10-Apr-27
 
Michael Frank, consultant 250,000 $0.20 1-Nov-17 1-Nov-22
Michael Frank, consultant 100,000 $0.325 29-Nov-17 29-Nov-24
Michael Frank, director & officer 1,500,000 $0.07 27-Dec-19 27-Dec-24
Michael Frank, director & officer 3,000,000 $0.33 25-May-20 25-May-30
 
Joshua Herman, consultant 125,334 $0.17 1-May-19 22-Apr-24
Joshua Herman, director 500,000 $0.07 27-Dec-19 27-Dec-24
 
1916241 Ontario Ltd., consultant 350,000 $0.205 8-Jun-18 8-Jun23
 
Pivotal Insight IP Inc., consultant 75,000 $0.205 21-Aug-18 21-Aug23
 
Allen Spektor, consultant 500,000 $0.19 11-Oct-18 11-Oct-20
 
Andrew LindzoAn, director 500,000 $0.07 27-Dec-19 27-Dec-24
 
Christian Scovenna, director 500,000 $0.07 27-Dec-19 27-Dec-24
 
Paige Capital Inc., consultant 350,000 $0.07 27-Dec-19 27-Dec-24
Paige Capital Inc., consultant 350,000 $0.33 25-May-20 25-May-30
 
8797668 Canada Ltd. consultant 500,000 $0.07 7-Feb-20 7-Feb-25
 
Mario Boscarino 850,000 $0.125 20-Apr-20 20-Apr-25
 
Jay Vieira, consultant 700,000 $0.33 25-May-20 25-May-30
 
Andrew Todd, consultant 100,000 $0.33 25-May-20 25-May-30
 

What Is Painting the Tape?

Painting the tape is a form of market manipulation whereby market players attempt to influence the price of a security by buying and selling it among themselves to create the appearance of substantial trading activity. The goal of painting the tape is to create the illusion of an increased interest in a stock to trick investors into buying shares, which would drive the price higher.

KEY TAKEAWAYS

  • Painting the tape is a type of market manipulation whereby market players attempt to influence the price of a security at the expense of investors.
  • Painting the tape increases volume and attracts investors, who then may push a price higher. The market manipulators will then sell their holdings to investors unaware of the manipulation.
  • Painting the tape is an illegal activity and prohibited by the SEC because it creates an artificial price.

Understanding Painting the Tape

Painting the tape is an illegal activity that is prohibited by the Securities and Exchange Commission (SEC) because it creates an artificial price. The SEC regulates and monitors financial activity in the markets to ensure that trading is done in a fair and orderly manner.1

The term originated in a bygone era when stock prices were largely transmitted on a ticker tape. Ticker tapes were first used to print the financial details of trades sent via a telegraph. The name was derived by the mechanical sound from the printers that printed the narrow strip of paper that contained stock quotes. Today, an electronic version of the ticker tape is used.2

Market manipulators know that high trading volumes in a security often attract the attention of investors. Painting the tape increases volume and attracts investors, who then may push the price higher. The market manipulators who have painted the tape will then sell their holdings—often acquired at much lower prices—to investors unaware of the manipulation. These investors are left "holding the bag" once the manipulation ceases, and the price of the stock declines steeply. 

Manipulators may paint the tape near the market's close in an attempt to boost a stock's price substantially at market close–a practice called marking the close. Closing prices are widely reported in the media and are closely watched by investors. Since most securities are valued on the basis of their closing prices, manipulators use this tactic to achieve higher market value for their holdings.

 



<< Previous
Bullboard Posts
Next >>